(Q38014312)

English

Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology

scientific article published on 30 May 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

27 August 2017

Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology (English)

1 reference

Europe PubMed Central

27 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

A Rostami-Hodjegan

1

1 reference

Europe PubMed Central

27 August 2017

language of work or name

0 references

publication date

30 May 2012

1 reference

Europe PubMed Central

27 August 2017

Clinical Pharmacology & Therapeutics

1 reference

Europe PubMed Central

27 August 2017

92

1 reference

Europe PubMed Central

27 August 2017

50-61

1 reference

Europe PubMed Central

27 August 2017

1

1 reference

Europe PubMed Central

27 August 2017

STUDIES ON THE DIFFUSION EFFECT UPON IONIC DISTRIBUTION : II. EXPERIMENTS ON IONIC ACCUMULATION.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

Torsten Teorell, the father of pharmacokinetics.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

Physiologically based pharmacokinetic (PBPK) modelling tools: how to fit with our needs?

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics: strategy and approach during the drug discovery phase with four case studies

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

Using Simcyp to project human oral pharmacokinetic variability in early drug research to mitigate mechanism-based adverse events

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

From preclinical to human--prediction of oral absorption and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach in an industrial setting: a workflow by using case example

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

Physiologically-based pharmacokinetics in drug development and regulatory science

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

Innovation: Rescuing drug discovery: in vivo systems pathology and systems pharmacology

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

Multiscale modeling in drug discovery and development: future opportunities and present challenges

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recogn

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

Assessing the efficiency of mixed effects modelling in quantifying metabolism based drug-drug interactions: using in vitro data as an aid to assess study power

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

Predicting drug interaction potential with a physiologically based pharmacokinetic model: a case study of telithromycin, a time-dependent CYP3A inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

The vision of toxicity testing in the 21st century: moving from discussion to action

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

Simulation and prediction of in vivo drug metabolism in human populations from in vitro data

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

The Simcyp population-based ADME simulator

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

Population-based mechanistic prediction of oral drug absorption

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

Modeling of intestinal drug absorption: roles of transporters and metabolic enzymes (for the Gillette Review Series).

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

The human intestinal cytochrome P450 "pie".

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

Human UDP-glucuronosyltransferases: metabolism, expression, and disease

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

Prediction of Phase I single-dose pharmacokinetics using recombinant cytochromes P450 and physiologically based modelling

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

Covariation of human microsomal protein per gram of liver with age: absence of influence of operator and sample storage may justify interlaboratory data pooling

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

Towards a quantitative framework for the prediction of DDIs arising from cytochrome P450 induction

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies -CYP2C9 and warfarin as an example

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

Prediction of in vivo drug clearance from in vitro data. II: potential inter-ethnic differences

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modelling.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients: expected variations in clearance

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

Modeling and predicting drug pharmacokinetics in patients with renal impairment.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut - the effect of diltiazem on th

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

Mass spectrometry-based absolute quantification of microsomal cytochrome P450 2D6 in human liver.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

Interindividual variability in hepatic expression of the multidrug resistance-associated protein 2 (MRP2/ABCC2): quantification by liquid chromatography/tandem mass spectrometry

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

LC-MS/MS mediated absolute quantification and comparison of bile salt export pump and breast cancer resistance protein in livers and hepatocytes across species.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

Measurement of the renal clearance of drugs

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

Effect of plasma protein binding on renal clearance of drugs.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

Genetic variants of the organic cation transporter 2 influence the disposition of metformin

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

Effects of genetic variation in the novel organic cation transporter, OCTN1, on the renal clearance of gabapentin

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

In vitro-in vivo correlation of hepatobiliary drug clearance in humans.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

Protein binding predictions in infants

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

Mechanistic approaches to volume of distribution predictions: understanding the processes.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

Determination of a quantitative relationship between hepatic CYP3A5*1/*3 and CYP3A4 expression for use in the prediction of metabolic clearance in virtual populations

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

Bottom-up modeling and simulation of tacrolimus clearance: prospective investigation of blood cell distribution, sex and CYP3A5 expression as covariates and assessment of study power

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

Bioavailability considerations in evaluating drug-drug interactions using the population pharmacokinetic approach.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

Regulatory experience with physiologically based pharmacokinetic modeling for pediatric drug trials.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

Metabolic/bariatric surgery Worldwide 2008.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

Significant increase in systemic exposure of atorvastatin after biliopancreatic diversion with duodenal switch

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

Significantly altered systemic exposure to atorvastatin acid following gastric bypass surgery in morbidly obese patients.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

21 January 2018

Modelling and simulation in prediction of human xenobiotic absorption, distribution, metabolism and excretion (ADME): in vitro-in vivo extrapolations (IVIVE)

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

7 January 2021

based on heuristic

inferred from DOI database lookup

Integrative and organ systems pharmacology: a new initiative from the National Institute of General Medical Sciences

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

7 January 2021

based on heuristic

inferred from DOI database lookup

Systems clinical pharmacology

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

7 January 2021

based on heuristic

inferred from DOI database lookup

The challenge of complexity

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

7 January 2021

based on heuristic

inferred from DOI database lookup

Physiologically based pharmacokinetic (PBPK) modeling: it is here to stay!

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

7 January 2021

based on heuristic

inferred from DOI database lookup

Precompetitive research: a new prescription for drug development?

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

7 January 2021

based on heuristic

inferred from DOI database lookup

Incorporating in vitro information on drug metabolism into clinical trial simulations to assess the effect of CYP2D6 polymorphism on pharmacokinetics and pharmacodynamics: dextromethorphan as a model application

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

7 January 2021

based on heuristic

inferred from DOI database lookup

Physicochemical determinants of human renal clearance

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

7 January 2021

based on heuristic

inferred from DOI database lookup

'In silico' simulations to assess the 'in vivo' consequences of 'in vitro' metabolic drug-drug interactions

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.65

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/CLPT.2012.65

1 reference

Europe PubMed Central

27 August 2017

1 reference

Europe PubMed Central

27 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38014312&oldid=1737315493"